BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) — Anaveon, a clinical-stage immuno-oncology company, announced today that it is presenting a poster of ANV600 at the 23rd Annual Meeting of the American Association for Cancer Research (AACR). will be held in Orlando, Florida from Friday, April 14, 2023 to Wednesday, April 19, 2023.

ANV600 is a novel bispecific compound combining an anti-IL-2 antibody/IL-2 fusion protein and a proprietary hPD-1 binding component for the specific delivery of IL-2 to tumor antigen-experienced PD-1+ T cells includes. Treatment with ANV600 leads to a dose-dependent increase in intratumoral, strain-like and cytotoxic PD-1+T cells in mice harboring subcutaneous B16F10 and MC38 tumors and significantly delays tumor growth.

“ANV600 is a powerful new targeted therapeutic with the potential to extend the benefits of IL-2 therapies to less immunogenic tumors,” said Christoph Huber, Anaveon’s Chief Scientific Officer. “We plan to start clinical trials in early 2024 to determine the therapeutic benefit in patients.”

The summary will be published Friday, March 31 in an online-only proceedings supplement in the AACR journal Cancer Research. The accompanying poster will be on display at Anaveon website on April 14 at 12:00 p.m. EDT.

Poster presentation details:
Tuesday, April 18, 9:00 a.m. – 12:30 p.m. EDT, Poster #4127
Title: ANV600 is a strong, cis-Non-alpha IL-2 signaling agonist that efficiently expands intratumoral CD8 stem-like T cells
Authors: Murer P, Salazar U, Egli N, Petersen L, Neubert P, Richter K, Stocker Ch, Rau A, Katopodis A, and Huber Ch

Anaveon is developing selective cytokine receptor agonists with the potential to therapeutically augment a patient’s immune system to respond to tumors. ANV419, currently in Ph II trials in multiple cancer indications, is believed to preferentially signal via the IL-2 beta/gamma receptor, resulting in extensive effector cell proliferation in patients. The follow-on agent ANV600 aims to…